PULM
Pulmatrix, Inc. NASDAQ$1.31
Mkt Cap $4.8M
52w Low $1.16
1.8% of range
52w High $9.37
50d MA $1.81
200d MA $3.60
P/E (TTM)
-0.9x
EV/EBITDA
-0.8x
P/B
1.2x
Debt/Equity
0.0x
ROE
-135.5%
P/FCF
-1.5x
RSI (14)
—
ATR (14)
—
Beta
1.97
50d MA
$1.81
200d MA
$3.60
Avg Volume
50.9K
About
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | — | -0.25 | — | 2.91 | +1.0% | +2.7% | -35.1% | -28.9% | -25.8% | -26.5% | -57.7% | — |
| Oct 16, 2025 | AMC | — | -0.24 | — | 4.64 | +5.0% | +3.7% | +8.0% | +6.5% | +5.8% | +4.5% | +2.4% | — |
| Aug 6, 2025 | AMC | — | -0.42 | — | 5.31 | -0.9% | -3.0% | -4.5% | -5.8% | -5.8% | -12.4% | -8.3% | — |
| May 15, 2025 | AMC | — | -0.50 | — | 6.52 | +5.5% | -0.6% | -0.3% | -1.2% | -6.0% | -1.2% | +33.4% | — |
| Mar 21, 2025 | AMC | — | -0.54 | — | 7.47 | +0.0% | -4.1% | -7.9% | -9.9% | -3.3% | -3.7% | -17.5% | — |
| Nov 8, 2024 | AMC | — | -0.71 | — | 2.05 | -1.5% | +1.0% | +0.0% | +73.7% | +129.3% | +220.0% | +191.2% | — |
| Aug 13, 2024 | AMC | — | -0.87 | — | 2.40 | -7.1% | -5.4% | -11.2% | -15.4% | -17.5% | -15.8% | -25.4% | — |
| May 10, 2024 | AMC | — | 0.23 | — | 1.78 | +3.9% | +0.0% | +0.6% | +2.8% | +7.9% | +7.3% | +10.7% | — |
| Mar 28, 2024 | AMC | -1.04 | -0.57 | +45.2% | 1.75 | -2.9% | -0.6% | -2.3% | +3.4% | +7.4% | +14.9% | +8.6% | — |
| Nov 9, 2023 | AMC | -1.05 | -1.03 | +1.9% | 1.85 | -2.7% | -6.0% | -3.2% | -1.6% | -2.7% | -4.3% | -1.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.47 | $2.47 | +0.0% | +2.0% | +1.6% | +1.2% | +0.8% | +0.4% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.78 | $2.78 | +0.0% | -3.2% | -5.4% | -4.0% | -3.2% | +2.5% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.97 | $4.00 | +0.8% | -2.5% | -4.0% | -6.8% | -5.5% | -4.5% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.60 | $6.94 | +5.2% | +1.7% | +3.5% | +1.5% | -0.3% | -0.2% |
Recent Filings
8-K · 8.01
!! High
Pulmatrix, Inc. -- 8-K 8.01: Material Event / Announcement
Pulmatrix completed a private placement exempt from Securities Act registration, raising capital from accredited investors under Regulation D without triggering public offering requirements.
Apr 21
8-K · 1.01
!!! Very High
Unknown — 8-K 1.01: Merger Agreement
PULM announced a merger agreement, which typically signals a major corporate transaction that will reshape the company's structure, ownership, and future prospects—investors should review deal terms, valuation, and timing immediately.
Mar 27
8-K · 1.02
!! High
Pulmatrix, Inc. -- 8-K 1.02: Material Agreement Terminated
Pulmatrix terminated its merger agreement, eliminating a planned combination and returning the company to independent status with potential strategic reassessment ahead.
Mar 2
8-K
Pulmatrix, Inc. -- 8-K Filing
Pulmatrix plans to license or monetize its migraine and inhalation assets, signaling a potential strategic shift to generate revenue from underutilized intellectual property.
Feb 26
Data updated apr 26, 2026 9:15pm
· Source: massive.com